FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895350704> ?p ?o ?g. }

• W2895350704 endingPage "7A" @default.
• W2895350704 startingPage "7A" @default.
• W2895350704 abstract "SESSION TITLE: Asthma and Comorbid Disease SESSION TYPE: Original Investigations PRESENTED ON: 10/10/2018 08:45 AM - 09:45 AM PURPOSE: Alpha-1 Antitrypsin Deficiency (A1ATD) is a genetic disease that results in abnormal alpha-1 antitrypsin protein polymers which cannot be released from hepatocytes. This results in low circulating alpha-1 antitrypsin and hepatotoxicity. Alpha-1 antitrypsin has a protective effect in the lungs by neutralizing pro-inflammatory enzymes, such as neutrophil elastase, and sufficiently low levels can result in emphysema.1 Bronchiectasis has also been associated with A1ATD since the original description of the disease.2 Augmentation therapy has been shown to have beneficial pulmonary effects in patients with emphysema, but outcome data in patients with bronchiectasis and the effects of augmentation therapy is lacking. METHODS: Patients with A1ATD and alpha-1 carrier status evaluated at Mayo Clinic Rochester from January 1, 2000 to October 1, 2016 were included in this retrospective review. Data relating to demographics, exacerbations, spirometry, and other causes of bronchiectasis were extracted. Patients with fewer than 12 months of augmentation therapy were excluded from outcome comparisons. RESULTS: 122 patients were included in the final analysis, of which 47 (38.5%) had bronchiectasis. 10 patients with bronchiectasis had MZ or MS genotypes. Compared to those without bronchiectasis, patients with bronchiectasis had a higher mean baseline rate of pulmonary exacerbations (0.73/year vs. 0.28/year, p=0.003). 34 patients received augmentation therapy, including 18 patients with bronchiectasis. Compared to patients without bronchiectasis who also received augmentation, those with bronchiectasis had a faster mean rate of decline in DLCO (-0.56 vs. +0.51 mL/min/mmHg/year, p=0.010), and a higher mean rate of post-treatment exacerbations (+1.28/year vs +0.5/year, p=0.011). Comparing patients with bronchiectasis and emphysema who did and did not receive augmentation, those who received augmentation therapy had more exacerbations compared to their baseline (+0.53/year vs. -0.31/year, p=0.019) and lower mean baseline percent predicted forced expiratory volume in one second (FEV1%) (46.5% vs. 67.8%, p=0.006) and DLCO (12.9 vs. 18.9 mL/min/mmHg, p=0.015), although the change over time was not significantly different. CONCLUSIONS: Bronchiectasis is a common finding in A1ATD, and is not exclusive to patients with ZZ genotypes. Patients with bronchiectasis in this cohort had higher rates of pulmonary exacerbations, regardless of treatment with augmentation therapy. CLINICAL IMPLICATIONS: The role of augmentation therapy for patients with bronchiectasis in the absence of emphysema is unclear and warrants additional studies. DISCLOSURES: No relevant relationships by Megan Dulohery Scrodin, source=Web Response No relevant relationships by Gregory Stroh, source=Web Response" @default.
• W2895350704 created "2018-10-12" @default.
• W2895350704 creator A5004014539 @default.
• W2895350704 creator A5071111074 @default.
• W2895350704 date "2018-10-01" @default.
• W2895350704 modified "2023-10-17" @default.
• W2895350704 title "BRONCHIECTASIS IN ALPHA-1 ANTITRYPSIN DEFICIENCY: A SINGLE-CENTER REVIEW" @default.
• W2895350704 doi "https://doi.org/10.1016/j.chest.2018.08.007" @default.
• W2895350704 hasPublicationYear "2018" @default.
• W2895350704 type Work @default.
• W2895350704 sameAs 2895350704 @default.
• W2895350704 citedByCount "0" @default.
• W2895350704 crossrefType "journal-article" @default.
• W2895350704 hasAuthorship W2895350704A5004014539 @default.
• W2895350704 hasAuthorship W2895350704A5071111074 @default.
• W2895350704 hasConcept C126322002 @default.
• W2895350704 hasConcept C2776042228 @default.
• W2895350704 hasConcept C2776317360 @default.
• W2895350704 hasConcept C2776780178 @default.
• W2895350704 hasConcept C2776914184 @default.
• W2895350704 hasConcept C2777714996 @default.
• W2895350704 hasConcept C2779379686 @default.
• W2895350704 hasConcept C2780333948 @default.
• W2895350704 hasConcept C2780535462 @default.
• W2895350704 hasConcept C71924100 @default.
• W2895350704 hasConcept C90924648 @default.
• W2895350704 hasConceptScore W2895350704C126322002 @default.
• W2895350704 hasConceptScore W2895350704C2776042228 @default.
• W2895350704 hasConceptScore W2895350704C2776317360 @default.
• W2895350704 hasConceptScore W2895350704C2776780178 @default.
• W2895350704 hasConceptScore W2895350704C2776914184 @default.
• W2895350704 hasConceptScore W2895350704C2777714996 @default.
• W2895350704 hasConceptScore W2895350704C2779379686 @default.
• W2895350704 hasConceptScore W2895350704C2780333948 @default.
• W2895350704 hasConceptScore W2895350704C2780535462 @default.
• W2895350704 hasConceptScore W2895350704C71924100 @default.
• W2895350704 hasConceptScore W2895350704C90924648 @default.
• W2895350704 hasIssue "4" @default.
• W2895350704 hasLocation W28953507041 @default.
• W2895350704 hasOpenAccess W2895350704 @default.
• W2895350704 hasPrimaryLocation W28953507041 @default.
• W2895350704 hasRelatedWork W2530759827 @default.
• W2895350704 hasRelatedWork W2552059164 @default.
• W2895350704 hasRelatedWork W2776194147 @default.
• W2895350704 hasRelatedWork W3095120941 @default.
• W2895350704 hasRelatedWork W3161651485 @default.
• W2895350704 hasRelatedWork W3163136137 @default.
• W2895350704 hasRelatedWork W3184930200 @default.
• W2895350704 hasRelatedWork W4381739206 @default.
• W2895350704 hasRelatedWork W1919835728 @default.
• W2895350704 hasRelatedWork W2595819642 @default.
• W2895350704 hasVolume "154" @default.
• W2895350704 isParatext "false" @default.
• W2895350704 isRetracted "false" @default.
• W2895350704 magId "2895350704" @default.
• W2895350704 workType "article" @default.